Table 3.
Association of treatment with miR-146a and pro-inflammatory cytokines in SLE patients.
| Treatment | miR-146a (M±SE) | IL-1β (M±SE) | IL-6 (M±SE) | IL-17 (M±SE) | IL-8 (M±SE) | TNF-α (M±SE) |
|---|---|---|---|---|---|---|
| Corticosteroid | ||||||
| Yes [91 (81%)] | 1.90 ± 0.18 | 21.30 ± 1.70 | 14.72 ± 1.08 | 1091.75 ± 217.04 | 75.55 ± 12.08 | 22.64 ± 2.44 |
| No [22 (19%)] | 1.93 ± 0.13 | 44.79 ± 3.03 | 10.10 ± 1.02 | 279.60 ± 85.31 | 29.24 ± 2.54 | 13.93 ± 1.11 |
| Hydroxychloroquine | ||||||
| Yes [95 (84%)] | 1.82 ± 0.19 | 22.07 ± 1.82 | 15.11 ± 1.16 | 1117.08 ± 228.13 | 27.53 ± 1.49** | 22.69 ± 2.63 |
| No [18 (16%)] | 1.96 ± 0.41 | 23.84 ± 6.95 | 9.86 ± 1.16 | 559.47 ± 338.83 | 46.52 ± 20.81 | 23.71 ± 4.21 |
| Cyclophosphamide | ||||||
| Yes [54 (48%)] | 1.74 ± 0.15** | 27.59 ± 3.07* | 12.58 ± 1.30* | 1031.69 ± 244.87 | 56.13 ± 12.56* | 20.96 ± 2.25 |
| No [59 (52%)] | 2.23 ± 0.44 | 20.39 ± 2.76 | 17.32 ± 2.30 | 1181.76 ± 434.83 | 27.30 ± 1.54 | 33.49 ± 7.41 |
| Azathioprine | ||||||
| Yes [71 (63%)] | 1.91 ± 0.19 | 21.04 ± 2.20 | 14.33 ± 1.28 | 1063.64 ± 265.03 | 61.0 ± 13.46 | 23.52 ± 2.66 |
| No [42 (37%)] | 1.87 ± 0.43 | 27.77 ± 3.87 | 15.67 ± 2.63 | 1118.09 ± 327.94 | 35.39 ± 8.82 | 28.74 ± 7.99 |
PC: P corrected; *: p < 0.05; **: p < 0.01; M: Mean; SE: Standard Error.